Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study

The Lancet Respiratory Medicine

Volumn 4, Issue 12, 2016, Pages 969-979

  McDonnell, Melissa J ^a,b,c   Aliberti, Stefano ^d,e   Goeminne, Pieter C ^f,g   Restrepo, Marcos I ^h   Finch, Simon ^j   Pesci, Alberto ⁱ   Dupont, Lieven J ^f   Fardon, Thomas C ^j   Wilson, Robert ^k   Loebinger, Michael R ^k   Skrbic, Dusan ^l,m   Obradovic, Dusanka ^l,m   De Soyza, Anthony ^b   Ward, Chris ^b   Laffey, John G ^c,n   Rutherford, Robert M ^a   Chalmers, James D ^j  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^d UNIVERSITY OF MILAN   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g AZ Nikolaas   (Belgium)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ UNIVERSITY OF MILANO BICOCCA   (Italy)

^j UNIVERSITY OF DUNDEE   (United Kingdom)

^k ROYAL BROMPTON HOSPITAL   (United Kingdom)

^l Institute for Pulmonary Diseases of Vojvodina Sremska Kamenica   (Serbia)

^m UNIVERSITY OF NOVI SAD   (Serbia)

ⁿ ST MICHAEL'S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRONCHIECTASIS; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MORTALITY RISK; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SERBIA; SURVIVAL ANALYSIS; UNITED KINGDOM; CLINICAL TRIAL; HOSPITALIZATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

AGED; BRONCHIECTASIS; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84997051957     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30320-4     Document Type: Article

References (30)

1. 1 Seitz, AE, Olivier, KN, Adjemian, J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest 142 (2012), 432–439.
2. 2 Leroy, L, Bayliss, E, Domino, M, et al. The Agency for Healthcare Research and Quality Multiple Chronic Conditions Research Network: overview of research contributions and future priorities. Med Care 52:suppl 3 (2014), S15–S22.
3. 3 Joish, VN, Spilsbury-Cantalupo, M, Operschall, E, Luong, B, Boklage, S, Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 11 (2013), 299–304.
4. 4 Gale, NS, Bolton, CE, Duckers, JM, Enright, S, Cockcroft, JR, Shale, DJ, Systemic comorbidities in bronchiectasis. Chron Respir Dis 9 (2012), 231–238.
5. 5 Lee, AL, Button, BM, Denehy, L, et al. Proximal and distal gastro-oesophageal reflux in chronic obstructive pulmonary disease and bronchiectasis. Respirology 19 (2014), 211–217.
6. 6 Mandal, P, Morice, AH, Chalmers, JD, Hill, AT, Symptoms of airway reflux predict exacerbations and quality of life in bronchiectasis. Respir Med 107 (2013), 1008–1013.
7. 7 McDonnell, MJ, Ahmed, M, Das, J, et al. Hiatal hernias are correlated with increased severity of non-cystic fibrosis bronchiectasis. Respirology 20 (2015), 749–757.
8. 8 Olveira, C, Olveira, G, Gaspar, I, et al. Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life. Qual Life Res 22 (2013), 597–605.
9. 9 Giron Moreno, RM, Fernandes Vasconcelos, G, Cisneros, C, Gómez-Punter, RM, Segrelles Calvo, G, Ancochea, J, Presence of anxiety and depression in patients with bronchiectasis unrelated to cystic fibrosis. Arch Bronconeumol 49 (2013), 415–420.
10. 10 Devaraj, A, Wells, AU, Meister, MG, Loebinger, MR, Wilson, R, Hansell, DM, Pulmonary hypertension in patients with bronchiectasis: prognostic significance of CT signs. AJR Am J Roentgenol 196 (2011), 1300–1304.
11. 11 Gülhan, PY, Bulcun, E, Gülhan, M, Çimen, D, Ekici, A, Ekici, M, Low cognitive ability in subjects with bronchiectasis. Respir Care 60 (2015), 1610–1615.
12. 12 Chung, WS, Lin, CL, Lin, CL, Kao, CH, Bronchiectasis and the risk of cancer: a nationwide retrospective cohort study. Int J Clin Pract 69 (2015), 682–688.
13. 13 Hurst, JR, Elborn, JS, De Soyza, A, COPD–bronchiectasis overlap syndrome. Eur Respir J 45 (2015), 310–313.
14. 14 Perry, E, Eggleton, P, De Soyza, A, Hutchinson, D, Kelly, C, Increased disease activity, severity and autoantibody positivity in rheumatoid arthritis patients with co-existent bronchiectasis. Int J Rheum Dis, 2015, 10.1111/1756-185X.12702 published online July 22.
15. 15 Loebinger, MR, Wells, AU, Hansell, DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 34 (2009), 843–849.
16. 16 Chalmers, JD, Goeminne, P, Aliberti, S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 189 (2014), 576–585.
17. 17 Martínez-García, MA, de Gracia, J, Vendrell Relat, M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 43 (2014), 1357–1367.
18. 18 Pasteur, MC, Bilton, D, Hill, AT, British Thoracic Society guideline for non-CF bronchiectasis. Thorax 65:suppl 1 (2010), i1–58.
19. 19 Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987), 373–383.
20. 20 Peduzzi, P, Concato, J, Kemper, E, Holford, TR, Feinstein, AR, A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49 (1996), 1373–1379.
21. 21 von Elm, E, Altman, DG, Egger, M, Pocock, SJ, Gøtzsche, PC, Vandenbroucke, JP, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007), 1453–1457.
22. 22 Collins, GS, Reitsma, JB, Altman, DG, Moons, KG, Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ, 350, 2015, g7594.
23. 23 Powell, HA, Iyen-Omofoman, B, Baldwin, DR, Hubbard, RB, Tata, LJ, Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. J Thorac Oncol 8 (2013), 6–11.
24. 24 Fabbri, LM, Luppi, F, Beghe, B, Rabe, KF, Complex chronic comorbidities of COPD. Eur Respir J 31 (2008), 204–212.
25. 25 Rennard, SI, Locantore, N, Delafont, B, et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc 12 (2015), 303–312.
26. 26 Mandal, P, Chalmers, JD, Graham, C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2 (2014), 455–463.
27. 27 Hnin, K, Nguyen, C, Carson, KV, Evans, DJ, Greenstone, M, Smith, BJ, Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. Cochrane Database Syst Rev, 8, 2015 CD001392.
28. 28 Divo, M, Cote, C, de Torres, JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186 (2012), 155–161.
29. 29 Vasquez, A, Logomarsino, JV, Anemia in chronic obstructive pulmonary disease and the potential role of iron deficiency. COPD 13 (2016), 100–109.
30. 30 Rademacher, J, Ringshausen, FC, Suhling, H, et al. Lung transplantation for non-cystic fibrosis bronchiectasis. Respir Med 115 (2016), 60–65.